In prostate cancer cells, adiponectin can prevent neovascularization by suppressing VEGF-A secretion (Gao et al., 2015), and adiponectin treatment has been shown to downregulate VEGF-B and VEGF-D mRNA expression while increasing the serum concentration of the anti-angiogenic factor IL-12 in mouse colon cancer cells (Moon et al., 2013). Here, ADIPOQ is linked to prostate carcinoma.